Activaero Cooperates with Bayer HealthCare in the Development of Inhaled Treatments

Bayer licenses rights to Activaero's pulmonary delivery platform

08-Oct-2008 - Germany

Activaero GmbH announced a licensing and option agreement with Bayer HealthCare AG on the development of inhaled treatments. Under the terms of the agreement, Activaero will receive an upfront payment and in case the option will be exerted subsequently milestone payments as well.

Dr. Gerhard Scheuch, Founder and CEO of Activaero commented: "This licensing deal represents a major milestone for Activaero and together with our scientific team, we look forward to supporting Bayer HealthCare throughout the upcoming development. We believe that pulmonary administration of drugs has a huge potential for the treatment of lung diseases and diseases which start in the lung. With this in mind, it will be exciting to develop innovative therapies with Bayer HealthCare, a world-wide leader in the pharmaceutical business for decades."

Activaero has been supported in the strategy, negotiation and process of this licensing transaction by Tytonis B.V.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances